This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:

The first disease-modifying drugs for Alzheimer's disease offer patients the ability to slow cognitive decline by targeting amyloid plaques in the brain. But a new study suggests that not all patients have the same opportunity to receive these treatments.

Research led by Michigan Medicine found that Black adults had 86% lower odds, and Hispanic adults had 79% lower odds of receiving anti-amyloid medication compared to non-Hispanic white adults.

The findings, published in Neurology, highlight potential disparities in access to a new class of Alzheimer's treatments as use of these therapies increases.

"The association we found between race/ethnicity and anti-amyloid medication use raises important questions about how patients are identified, evaluated and ultimately selected for treatment," said Melissa Elafros, co-first author and Andrea and Lawrence A. Wolfe Research Professor at the University of Michigan Medical School.

"It's critical that we understand and address the disparities we are seeing today so that as many patients as possible receive benefits."

From a database of over 1 million adults with mild cognitive impairment or dementia, the research team identified 2,427 patients who received anti-amyloid medication and compared them to a similar group of untreated patients.

They found that race, ethnicity and health comorbidities were strongly associated with whether patients received treatment.

Participants who faced greater social and economic disadvantages, as measured by factors including income, education and access to housing and neighborhood resources, were nearly half as likely to receive the latest treatments.

Source link